Mapi Pharma

Formulations That Meet Unmet Patient Needs

Focused on long acting
depot injections

Developing Finished Dosage Forms and a Portfolio of APIs

Fully integrated GMP
manufacturing facilities

Pipeline of Multiple Late Stage Products

In Phase III for RMS and Phase II for
PPMS for treating MS

We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.

Focus

Our main focus is on developing long acting depot injectable drugs.

Programs

Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica^®) for pain.

Latest News

Mapi Pharma is Seeking New Depot Product Partnerships: Management to Participate in 7th Annual Evercore HealthCONx Conference

December 2, 2024

NESS ZIONA, Israel – Dec. 2, 2024 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 7th Annual Evercore HealthCONx...

Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlights Latest Results on GA Depot in Relapsing Multiple Sclerosis at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023

October 10, 2023

Meeting to feature latest clinical findings on GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) NESS ZIONA, Israel – Oct. 10, 2023 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development...